Therapeutic Advances in the Management of Hyperkalemia with
End Stage Renal Disease: Improving Clinical and Cost
Outcomes in an Evolving Treatment Paradigm

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management
of Hyperkalemia in patients with End Stage Renal Disease

These are archives of live webinars held between October 21 and October 26, 2020.
If you participated in any of the live webinars, you are not eligible to
claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.

These activities are valid from November 1, 2020 to November 1, 2022


This series is supported by an educational grant from AstraZeneca


 
Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Hyperkalemia, also known has high potassium, is an elevated level of potassium in the blood. Typically this results in no symptoms, but occasionally when severe it results in palpitations, muscle pain, muscle weakness, or numbness. Decreased kidney function is a major cause of hyperkalemia, especially in chronic kidney disease (CKD). Hyperkalemia occurs in up to 10% of hospitalized patients and is associated increased morbidity if left unaddressed. Fortunately for patients who experience hyperkalemia, new therapies have become available in recent years that have shown improved efficacy and safety. Attendees will be updated on these novel options and how they can integrate them into the treatment paradigm and optimize costs.


A Deeper Look into Novel Potassium Binders in the Management of Hyperkalemia with End Stage Renal Disease: Individualizing Treatment for Improved Clinical and Cost Outcomes

  1. Analyze the clinical and economic burden of hyperkalemia and the impact of suboptimal management on outcomes
  2. Identify the risk factors and pathophysiologic mechanisms associated with the development of hyperkalemia in key patient populations
  3. Evaluate recent potassium binders in terms of safety, efficacy, labeling, dosing and role in hyperkalemia with end stage renal disease management strategies
  4. Identify patients with hyperkalemia with end stage renal disease who would potentially benefit from a novel potassium binder therapy
       Physician, Nursing and CMCN credits valid to November 1, 2022

Comparative Effectiveness and Coordinated Care in Hyperkalemia with End Stage Renal Disease: What Does Managed Care Need to Know about Newer Therapies?

  1. Analyze the economic burden of hyperkalemia and the impact of suboptimal management on outcomes
  2. Evaluate recent potassium binders in terms of safety, efficacy, labeling, dosing and role in hyperkalemia with end stage renal disease management strategies
  3. Integrate the latest clinical and pharmacoeconomic data into evidence-based formulary decisions and benefits design
  4. Apply formulary strategies to assist in appropriate treatment choices and stem the high healthcare utilization associated with hyperkalemia
  5. Analyze methods to enable optimal cost management of potassium binders to be realized by multiple hyperkalemia stakeholders including managed care organizations
       Physician, Nursing and CMCN credits valid to November 1, 2022

Improving Patient Adherence and Quality of Life in Hyperkalemia with End Stage Renal Disease: Strategies for Detecting and Managing Adverse Events Associated with Novel Therapies

  1. Assess challenges to patient adherence and quality of life in hyperkalemia with end stage renal disease
  2. Explore strategies to monitor and manage adverse events associated with newer potassium binders in hyperkalemia in order to improve patient adherence and quality of life
  3. Advance the long-term management of hyperkalemia with end stage renal disease in provider and managed care settings through measures that facilitate at-risk patient monitoring, promote patient/provider education, and integrate newer therapies for optimal patient outcomes
  4. Review recent clinical data around the safety of novel potassium binder therapies and their effect on patient quality of life in hyperkalemia, especially in patients with end stage renal disease
       Physician, Nursing and CMCN credits valid to November 1, 2022